ArticleJournal of inflammation research2025
The Combined Prognostic Value of the Systemic Immune-Inflammation Index and LDL-C in Patients with AMI Undergoing PPCI.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combined prognostic impact of the systemic immune-inflammation index (SII) and low-density lipoprotein cholesterol (LDL-C) after primary percutaneous coronary intervention (PPCI) in acute myocardial infarction (AMI) remains unclear. We evaluated their joint predictive value for clinical outcomes. Methods: We retrospectively analyzed 487 AMI patients who underwent PPCI at the Affiliated Hospital of Xuzhou Medical University between January 2019 and December 2021. SII and LDL-C were assessed at baseline and 1 month post-discharge. Using the guideline LDL-C target (<1.4 mmol/L or ≥50% reduction) and a receiver operating characteristic (ROC)-derived optimal SII cutoff (676.6 × 10 Results: Versus the both off-target group, the both on-target group had significantly better outcomes (P < 0.001). The SII on-target only group also outperformed the LDL-C on-target only group (P < 0.001). Consistently, the both off-target group had markedly worse outcomes relative to the both on-target group (HR = 69.2; 95% CI: 16.8-285.0; P < 0.001). At 1 month, SII showed good discrimination for MACEs (AUC = 0.76). Conclusion: One month after PPCI, simultaneous achievement of SII and LDL-C targets was associated with a substantially lower 1-year risk of MACEs. Combined control of inflammation and lipids provided incremental benefit beyond lipid lowering alone, supporting a dual-target strategy in secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.